Literature DB >> 16055823

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.

W Wolfgang Fleischhacker1, Jonathan Rabinowitz, Georg Kemmler, Mariëlle Eerdekens, Angelika Mehnert.   

Abstract

BACKGROUND: The extent to which antipsychotics improve patients' well-being is uncertain. AIMS: To examine psychopathology and patient-rated functioning and well-being in patients treated with risperidone.
METHOD: In a 1-year, open-label, international multicentre trial of long-acting risperidone in 615 stable adult patients with schizophrenia, self-rated functioning and well-being were measured every 3 months using the Short Form 36-item questionnaire (SF-36). Psychopathology was quantified using the Positive and Negative Syndrome Scale (PANSS).
RESULTS: Significant improvements were found on the SF-36 mental component summary score and vitality and social functioning scales. PANSS and mental component summary scores were moderately correlated.
CONCLUSIONS: Patient-reported functioning and well-being appear to differ from investigator-rated psychotic symptoms. Patient-rated well-being should be assessed with symptoms to help measure treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055823     DOI: 10.1192/bjp.187.2.131

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  19 in total

1.  Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.

Authors:  Sonia Dollfus; Cyril Mach; Rémy Morello
Journal:  Schizophr Bull       Date:  2015-11-12       Impact factor: 9.306

Review 2.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

3.  Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.

Authors:  E Fakra; S Khalfa; D Da Fonseca; N Besnier; P Delaveau; J M Azorin; O Blin
Journal:  Psychopharmacology (Berl)       Date:  2008-06-25       Impact factor: 4.530

4.  PerserisTM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

Authors:  Andrew Karas; Gary Burdge; Jose A Rey
Journal:  P T       Date:  2019-08

5.  Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder.

Authors:  Alex Hofer; Maria A Rettenbacher; Christian G Widschwendter; Georg Kemmler; Martina Hummer; W Wolfgang Fleischhacker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-29       Impact factor: 5.270

Review 6.  Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

Authors:  Hans-Jürgen Möller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults.

Authors:  Pamela DeRosse; George C Nitzburg; Melanie Blair; Anil K Malhotra
Journal:  Schizophr Res       Date:  2017-10-19       Impact factor: 4.939

Review 8.  Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.

Authors:  Pierre Chue; Robin Emsley
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Flourishing With Psychosis: A Prospective Examination on the Interactions Between Clinical, Functional, and Personal Recovery Processes on Well-being Among Individuals with Schizophrenia Spectrum Disorders.

Authors:  Randolph C H Chan; Winnie W S Mak; Floria H N Chio; Alan C Y Tong
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.